Circulating tumor cells count as a predictor of survival in lung cancer

Syrigos, Konstantinos; Fiste, Oraianthi; Charpidou, Andriani; Grapsa, Dimitra

doi:10.1016/j.critrevonc.2018.03.004

Cited by 41 publications

(34 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies investigated the prognostic role of CTCs in different types of tumors, including NSCLC [11]. The first of these studies was performed in 101 chemo-naïve advanced NSCLC patients and showed a prognostic significance of CTCs obtained with CellSearch.…”

Section: Circulating Tumor Cellsmentioning

confidence: 99%

Liquid Biopsy in Non-Small Cell Lung Cancer: Highlights and Challenges

Rijavec

Coco

Genova

et al. 2019

Cancers

View full text Add to dashboard Cite

Non-small cell lung cancer is one leading cause of death worldwide, and patients would greatly benefit from an early diagnosis. Since targeted and immunotherapies have emerged as novel approaches for more tailored treatments, repeated assessments of the tumor biology have become pivotal to drive clinical decisions. Currently, tumor tissue biopsy is the gold standard to investigate potentially actionable biomarkers, but this procedure is invasive and may prove inadequate to represent the whole malignancy. In this regard, liquid biopsy represents a minimally invasive and more comprehensive option for early detection and investigation of this tumor. Today, cell-free DNA is the only approved circulating marker to select patients for a targeted therapy. Conversely, the other tumor-derived markers (i.e., circulating tumor cells, miRNAs, exosomes, and tumor educated platelets) are still at a pre-clinical phase, although they show promising results for their application in screening programs or as prognostic/predictive biomarkers. The main challenges for their clinical translation are the lack of reliable cutoffs and, especially for miRNAs, the great variability among the studies. Moreover, no established tool has been approved for circulating tumor cells and exosome isolation. Finally, large prospective clinical trials are mandatory to provide evidence of their clinical utility.

show abstract

Section: Circulating Tumor Cellsmentioning

confidence: 99%

Liquid Biopsy in Non-Small Cell Lung Cancer: Highlights and Challenges

Rijavec

Coco

Genova

et al. 2019

Cancers

View full text Add to dashboard Cite

show abstract

“…Circulating tumor cells (CTCs) are a subset of tumor cells with the ability to migrate from the primary site, intravasate into nearby blood and/or lymphatic vessels, and survive in the challenging microenvironment of the bloodstream. CTCs can also extravasate from the vascular system into the surrounding tissues and form micro metastases in secondary organs with the potential for growth into macroscopic tumors (2). In SCLC, the presence of ≥2 CTCs/7.5 mL of peripheral venous blood was found in 75% of patients with either limited disease or extensive disease (3).…”

Section: Introductionmentioning

confidence: 99%

Incorporation of circulating tumor cells and whole-body metabolic tumor volume of 18F-FDG PET/CT improves prediction of outcome in IIIB stage small-cell lung cancer

Zhu

Wang

et al. 2018

Chinese Journal of Cancer Research

View full text Add to dashboard Cite

ObjectiveWe investigated the correlation between the number of circulating tumor cells (CTCs) and whole-body metabolic tumor volume (WBMTV) measured by 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT). The aim was to evaluate the value of the incorporation of CTC number and WBMTV in the prognostic prediction of stage III small-cell lung cancer (SCLC). MethodsOne hundred and twenty-nine patients were enrolled in this study. All patients were treated with four cycles of a platinum-based regimen and concurrent chest irradiation, followed by prophylactic cranial irradiation. Blood samples for CTC analysis were obtained from 112 patients before the initiation of chemotherapy (as a baseline), after cycle 1 and after cycle 4. CTCs were measured using the CELLSEARCH® system. The patients underwent pretreatment FDG PET/CT WBMTV, which included all malignant lesions. The Spearman rank test was used to determine the correlation among CTC counts, WBMTV and disease stage. Overall survival (OS) and progression-free survival (PFS) curves were produced using the Kaplan-Meier method, and survival differences between groups were assessed by the log-rank test. ResultsThe number of CTCs at baseline did not correlate with WBMTV before the initiation of therapy (P=0.241). The number of CTCs at baseline and the WBMTV before the initiation of therapy were independent relevant factors for PFS and OS. The subgroup analysis (Group A: CTC count >19.5 and a WBMTV >266.5 cm 3; Group B: CTC count >19.5 and a WBMTV ≤266.5 cm 3; Group C: CTC count ≤19.5 and a WBMTV >266.5 cm 3; Group D: CTC count ≤19.5 and a WBMTV ≤266.5 cm3) showed that the differences were statistically significant in the median PFS (Group A vs. D, P<0.001; Group Bvs. D, P=0.018; Group C vs. D, P=0.029) and in the median OS (Group A vs. D, P<0.001; Group Bvs. D, P=0.012). ConclusionsCTC number and WBMTV are related to progression and death in patients with SCLC. The incorporation of CTC number and WBMTV scans can provide a detailed prognostic prediction for SCLC.

show abstract

“…43 Overall, clinical evidence supports the potential of the CTC count as a predictor of survival in both patients with small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). 12 For patients with SCLC, which is a particularly aggressive lung cancer affecting approximately 15% of patients, CTCs are capable of distinguishing between Circulating Tumor Cells as Biomarkers/Jin et al chemorefractory and chemosensitive SCLC. 44 Several recent studies have found that CTCs also can be useful for NSCLC, which accounts for approximately 80% of lung cancers.…”

Section: Ctcs and Lung Cancermentioning

confidence: 99%

“…CTCs have shown strong potential in the diagnosis of lung cancer, and currently are being actively considered for their prognostic capacity as well . Overall, clinical evidence supports the potential of the CTC count as a predictor of survival in both patients with small cell lung cancer (SCLC) and non–small cell lung cancer (NSCLC) . For patients with SCLC, which is a particularly aggressive lung cancer affecting approximately 15% of patients, CTCs are capable of distinguishing between chemorefractory and chemosensitive SCLC .…”

Section: Introductionmentioning

confidence: 97%

“…Since the early 21st century, clinical studies have supported earlier case-based observations that high levels of CTCs predict poor survival rates. [10][11][12] However, more detailed analyses have shown that simple quantification of CTCs can predict survival in only certain subgroups of patients; for example, in patients with breast cancer, the number of CTCs after the initiation of hormonal treatment is correlated with survival, but the number of CTCs before the initiation of hormonal treatment is not. 11 This suggests that it is certain types of CTCs, rather than CTCs in general, that are correlated with poor survival.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Current progress in the clinical use of circulating tumor cells as prognostic biomarkers

Jin

Chen

Lan³

et al. 2019

Cancer Cytopathology

View full text Add to dashboard Cite

The process of metastasis is characterized by the shedding of tumor cells into the bloodstream, where they are transported to other parts of the body to seed new tumors. These cells, known as circulating tumor cells (CTCs), have the potential to reveal much about an individual cancer case, and theoretically can aid in the prediction of outcomes and design of precision treatments. Recent advances in technology now allow for the robust and reproducible characterization of CTCs from a simple blood draw. Both the number of circulating cells and important molecular characteristics correlated with clinical phenotypes such as drug resistance can be obtained and used for real‐time prognostic analysis. Molecular characterization can provide a snapshot of the activity of the main tumor (serving as a “liquid biopsy”) and early warnings concerning changes such as the development of resistance, and aid in predicting the efficacy of different therapeutic approaches for treatment optimization. Herein, the authors review the current clinical use of CTCs as prognostic biomarkers for several different cancers. The quantification of CTCs can lead to more accurate staging and decision making regarding options such as adjuvant chemotherapy.

show abstract

Circulating tumor cells count as a predictor of survival in lung cancer

Cited by 41 publications

References 75 publications

Liquid Biopsy in Non-Small Cell Lung Cancer: Highlights and Challenges

Liquid Biopsy in Non-Small Cell Lung Cancer: Highlights and Challenges

Incorporation of circulating tumor cells and whole-body metabolic tumor volume of 18F-FDG PET/CT improves prediction of outcome in IIIB stage small-cell lung cancer

Current progress in the clinical use of circulating tumor cells as prognostic biomarkers

Contact Info

Product

Resources

About